Is Aquestive Therapeutics, Inc. (NASDAQ:AQST) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aquestive Therapeutics, Inc. at current levels.
Anaphylm is the first credible needle-free epinephrine, and the market is still pricing AQST like a film-strip royalty stub.
Where AQST is headed
Anaphylm is the whole story, and by late 2027 it should be sitting on pharmacy shelves as the first sublingual film alternative to the auto-injector. The EpiPen monopoly is a $1.5 billion US market defended by a device most patients won't carry because it's the size of a magic marker and costs them an emergency-room reflex to use. A postage-stamp film that dissolves under the tongue is the kind of product change that doesn't need clever marketing. Parents of kids with peanut allergies, college students, anyone who has ever stared at an auto-injector and hesitated, this is the product they've been asking for.
Read the full Compass Direction on AQST
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.99).
See the full AQST analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Aquestive Therapeutics, Inc. (NASDAQ:AQST) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Aquestive Therapeutics, Inc. at current levels. Anaphylm is the first credible needle-free epinephrine, and the market is still pricing AQST like a film-strip royalty stub.
What is AQST's Compass Score?
Aquestive Therapeutics, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for AQST?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the AQST page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.